Graphique du cours de l'action VNRX
VNRX Gagner
VolitionRX Ltd
$0
0%
$0
À la fermeture : Apr 30, 16:00:00 GMT-4
$0
0%
$0
Pré-Marché: May 01, 10:12:36 GMT-4
Retour
VolitionRX Ltd (VNRX) Gagner
Statistiques clés
Clôture préc.
--
Prix d'ouverture
--
Plage de la journée
-
Plage de 52 semaines
-
Volume
--
Volume moyen
--
Rendement en dividend
--
BPA (TTM)
--
Capitalisation boursière
--
Qu’est-ce que VNRX ?
VolitionRX Ltd. engages in the development of blood-based cancer tests to help diagnose a range of cancers. The company is headquartered in Henderson, Nevada and currently employs 85 full-time employees. The company went IPO on 2015-02-06. The firm is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
Fonctionnalités
© 2026 Edgen fonctionné par
